Hawaii Cannabis logo

If nothing else we can all be certain that the U.S. Federal government can no longer agree on the value of Cannabis.

Should an agreement be reached between health officials and law enforcement officials before prohibiting the use of Cannabis?

The following evidence suggests, any law prohibiting the use of anything can be created and strictly enforced in the absence of agreement. Awareness and understanding aside, it would appear that whomever has the gun, has the power when it comes to law making and law enforcement in the U.S.

This is the not the promise of the U.S. Constitution which states in it’s Preamble,

“We the People of the United States, in Order to form a more perfect Union, establish Justice, insure domestic Tranquility, provide for the common defense, promote the general Welfare, and secure the Blessings of Liberty to ourselves and our Posterity, do ordain and establish this Constitution for the United States of America.” –U.S. Constitution

DEA’S POSITION ON MARIJUANA
“Marijuana is properly categorized under Schedule I of the Controlled Substances Act (CSA), 21 U.S.C. § 801, et seq. The clear weight of the currently available evidence supports this
classification, including evidence that smoked marijuana has a high potential for abuse, has no accepted medicinal value in treatment in the United States, and evidence that there is a general lack of accepted safety for its use even under medical supervision.” – U.S. Drug Enforcement Agency

U.S. Department of Health’s Position on Marijuana

“ABSTRACT – Cannabinoids have been found to have antioxidant properties, unrelated to NMDA receptor antagonism. This new found property makes cannabinoids useful in the treatment and prophylaxis of wide variety of oxidation associated diseases, such as ischemic, age-related, inflammatory and autoimmune diseases. The cannabinoids are found to have particular application as neuroprotectants, for example in limiting neurological damage following ischemic insults, such as stroke and trauma, or in the treatment of neurodegenerative diseases, such as Alzheimer’s disease, Parkinson’s disease and HIV dementia. Nonpsychoactive cannabinoids, such as cannabidoil, are particularly advantageous to use because they avoid toxicity that is encountered with psychoactive cannabinoids at high doses useful in the method of the present invention. A particular disclosed class of cannabinoids useful as neuroprotective antioxidants is formula (I) wherein the R group is independently selected from the group consisting of H, CH3, and COCH3.” – U.S. Patent#US6630507 B1

 

PATENT CITATIONS
Cited Patent Filing date Publication date Applicant Title
US2304669 Aug 16, 1940 Dec 8, 1942 Adams Roger Isolation of cannabidiol
US4876276 Oct 26, 1987 Oct 24, 1989 Yissum Research Development Co. Of The Hebrew University Of Jerusalem (3S-4S)-7-hydroxy-Δ6 -tetrahydrocannabinols
US5227537 Jan 8, 1992 Jul 13, 1993 Heinrich Mack Nachf. Method for the production of 6,12-dihydro-6-hydroxy-cannabidiol and the use thereof for the production of trans-delta-9-tetrahydrocannabinol
US5284867 Apr 8, 1992 Feb 8, 1994 Yissum Research Development Company Of The Hebrew University In Jerusalem NMDA-blocking pharmaceutical compositions
US5434295 Feb 7, 1994 Jul 18, 1995 Yissum Research Development Company Neuroprotective pharmaceutical compositions of 4-phenylpinene derivatives and certain novel 4-phenylpinene compounds
US5462946 Mar 20, 1992 Oct 31, 1995 The United States Of America As Represented By The Department Of Health And Human Services Nitroxides as protectors against oxidative stress
US5512270 Aug 31, 1994 Apr 30, 1996 Duke University Method of inhibiting oxidants using alkylaryl polyether alcohol polymers
US5521215 Feb 7, 1994 May 28, 1996 Ramot University Authority For Applied Research And Industrial Development Ltd. NMDA-blocking pharmaceuticals
US5538993 Feb 7, 1994 Jul 23, 1996 Yissum Research Development Company Certain tetrahydrocannabinol-7-oic acid derivatives
US5635530 Sep 11, 1992 Jun 3, 1997 Yissum Research Development Company Of The Hebrew University Of Jerusalem (3S,4S)-delta-6-tetrahydrocannabinol-7-oic acids and derivatives thereof, processors for their preparation and pharmaceutical compositions containing them
US5696109 Jun 7, 1995 Dec 9, 1997 Eukarion, Inc. Synthetic catalytic free radical scavengers useful as antioxidants for prevention and therapy of disease
US6410588 Apr 14, 1999 Jun 25, 2002 The Mathilda And Terence Kennedy Institute Of Rheumatology Use of cannabinoids as anti-inflammatory agents
EP0427518A1 Nov 6, 1990 May 15, 1991 Yissum Research Development Company Of The Hebrew University Of Jerusalem NMDA-Blocking compounds, pharmaceutical compositions, their preparation and use
EP0576357A1 Jun 23, 1993 Dec 29, 1993 Sanofi Pyrazole derivatives, process for their preparation and pharmaceutical compositions containing them
EP0656354A1 Nov 29, 1994 Jun 7, 1995 Sanofi Substituted N-piperidino 3-pyrazolecarboxamide
EP0658546A1 Dec 15, 1994 Jun 21, 1995 Sanofi Novel 3-pyrazolecarboxamide derivatives with cannabinoid receptor affinity
WO1993005031A1 Sep 11, 1992 Mar 18, 1993 Yissum Res Dev Co (3s,4s)-delta-6-tetrahydrocannabinol-7-oic acids and derivatives thereof, processes for their preparation and pharmaceutical compositions containing them
WO1994012667A1 Nov 29, 1993 Jun 9, 1994 Us Department Of The Army Inhibitors of arachidonic acid metabolites for preventing neurological damage
WO1996012485A1 Oct 18, 1995 May 2, 1996 Lilly Co Eli Treatment of disorders with duloxetine
WO1996018600A1 Dec 13, 1995 Jun 20, 1996 Valle Francesco Della Amides of mono and bicarboxylic acids with amino acids or glycosamines, selectively active on the cannabinoid peripheral receptor
WO1997019063A1 Nov 21, 1996 May 29, 1997 Barth Francis Pyrazole derivatives, method for preparing same, and pharmaceutical compositions containing said derivatives
WO1999053917A1 * Apr 21, 1999 Oct 28, 1999 Julius Axelrod Cannabinoids as antioxidants and neuroprotectants